Array BioPharma explained
| Array BioPharma |
| Type: | Subsidiary |
| Traded As: | NASDAQ: |
| Industry: | Oncology
Medication |
| Hq Location City: | Boulder, Colorado |
| Hq Location Country: | United States |
| Revenue: | $173.8 million (2018) |
| Parent: | Pfizer |
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]
In November 2000, the company became a public company via an initial public offering.[2]
In June 2019, Pfizer acquired the company for approximately $11 billion.[3]
Discovery of FDA Approved Small Molecules
- MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
- BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
- KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
- VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)
Notes and References
- Web site: Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company. 2020-07-28. BioSpace. en-US.
- News: Array IPO up 17% . . November 17, 2000.
- Web site: Pfizer acquires Array BioPharma, valued at $11.4 billion. 2020-07-29. Rappler. 18 June 2019 . en.
